


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on September 17, 2007.


Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Examining Group 1623
Patent Application
Docket No. MET-016XDT
Serial No. 10/780,948

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Patrick T. Lewis, Ph.D.
Art Unit : 1623
Applicants : Mark D. Erion, Paul D. van Poelje
Serial No. : 10/780,948
Filed : February 17, 2004
Conf. No. : 2285
For : Combination of FB Pase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is attached. However, Applicants have not submitted copies of the U.S. patents or published U.S. Patent Applications cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants note that published International Applications cited as 37 and 38 on the attached form PTO/SB/08, were written in a foreign language. However, an English language abstract is

provided in the references. Applicants respectfully request that the references be made of record and considered in the examination of the subject application.

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. The fee of \$180.00 was paid at the time this Information Disclosure Statement was filed.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement. The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/jps/sl

Attachments: Form PTO/SB/08; copies of references cited therein.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/780,948
				Filing Date	February 17, 2004
				First Named Inventor	Mark D. Erion
				Art Unit	1623
				Examiner Name	Patrick T. Lewis, Ph.D.
Sheet	1	of	9	Attorney Docket Number	MET-016XDT

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if Known)			
	1.	3,454,635	07-01-1969	Muth Karl, et al.	All
	2.	3,551,422	12-29-1970	Tesoro, et al.	All
	3.	3,650,670	03-01-1972	Tesoro, et al.	All
	4.	3,657,282	04-18-1972	Christensen, et al.	All
	5.	3,822,296	07-02-1974	Christensen, et al.	All
	6.	3,931,206	01-06-1976	Bowler, et al.	All
	7.	4,000,305	12-26-1976	Bowler, et al.	All
	8.	4,046,841	09-06-1977	Foster, et al.	All
	9.	4,092,323	05-30-1978	Foster, et al.	All
	10.	4,587,256	05-06-1986	Hasler, et al.	All
	11.	4,746,654	05-24-1988	Breliere, et al.	All
	12.	4,876,248	10-24-1989	Breliere, et al.	All
	13.	4,939,130	07-01-1990	Jaeggi, et al.	All
	14.	5,116,919	05-01-1992	Buzinkai, et al.	All
	15.	5,133,972	07-28-1992	Ferrini et al.	All
	16.	5,142,000	08-01-1992	Wheland, et al.	All
	17.	5,550,276	08-27-1996	Wirth, et al.	All
	18.	5,610,210	03-11-1997	Holderbaum, et al.	All
	19.	5,728,650	03-01-1998	Fisher, et al.	All
	20.	5,731,299	03-01-1998	Ebetino, et al.	All
	21.	5,798,340	08-25-1998	Bischofberger, et al.	All
	22.	5,925,656	07-20-1999	Kallam, et al.	All
	23.	5,958,904	09-28-1999	Cordi, et al.	All
	24.	5,985,858	11-16-1999	Miyata et al.	All
	25.	6,001,862	12-14-1999	Maeda, et al.	All
	26.	6,030,990	02-29-2000	Maeda, et al.	All
	27.	6,110,903	08-29-2000	Kasibhatla, et al.	All
	28.	6,284,672	09-01-2001	Yu, et al.	All
	29.	6,399,782	06-04-2002	Kasibhatla, et al.	All
	30.	6,008,237	12-01-1999	Sahoo, et al.	All
	31.	6,037,335 B1	03-14-2000	Takashima, et al.	All
	32.	6,054,587	04-01-2000	Reddy, et al.	All
	33.	6,284,748 B1	08-01-2001	Dang, et al.	All
	34.	6,294,672 B1	09-01-2001	Reddy, et al.	All
	35.	2004/0167178	08-26-2004	Erion, et al.	All

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/780,948
				Filing Date	February 17, 2004
				First Named Inventor	Mark D. Erion
				Art Unit	1623
				Examiner Name	Patrick T. Lewis, Ph.D.
Sheet	2	of	9	Attorney Docket Number	MET-016XDT

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² Number ³ Kind Code ⁴ (if known)				
	36.	AU 654899B B2	09-09-1993	De Nanteuil, et al.	All	
	37.	DE 195 01 843 A1	06-20-1996	Vass, et al.	All	
	38.	DE 40 29 444 A1	03-28-1991	Maier, et al.	All	
	39.	EP 0 033 195 A1	08-05-1981	Gacek, M.	All	
	40.	EP 0 034 480A2	08-26-1981	Gigg, et al.	All	
	41.	EP 0 186 405 A2	07-02-1986	Benedict, et al.	All	
	42.	EP 0 230 068 A2	07-29-1987	Benedict, et al.	All	
	43.	EP 0 243 173 B1	06-26-1991	Oku, et al.	All	
	44.	EP 0 354 322 A2	02-14-1990	DeVries, et al.	All	
	45.	EP 0 528 760 A1	02-24-1993	Hayakawa, et al.	All	
	46.	EP 0 559 079 A1	09-08-1993	Phan, et al.	All	
	47.	EP 0 603 419 A1	06-29-1994	Shibata, et al.	All	
	48.	EP 0 620 227 A1	10-19-1994	Yoshikawa, et al.	All	
	49.	EP 0 353 969 A1	02-07-1990	Wheland, et al.	All	
	50.	GB 1343022	01-09-1974	British Oxygen CO. LTD.	All	
	51.	GB 2271113	04-06-1994	Ichiro, et al.	All	
	52.	JP 6-306089A2 (abstract only)	11-01-1994	Shoji, et al.	All	
	53.	JP 09-048770 (abstract only)	02-18-1997	Sankyo, Co., Ltd.	All	
	54.	WO 01/32157	05-10-2001	Bristol-Myers Squibb Company	All	
	55.	WO 02/00673	01-03-2002	Rademacher, et al.	All	
	56.	WO 06/023515 A2	03-02-2006	Metabasis Therapeutics, Inc.	All	
	57.	WO 90/09163	08-23-1990	Gensia Pharma	All	
	58.	WO 91/19721	12-26-1991	Glazier, A.	All	
	59.	WO 92/11269 A1	07-09-1992	Pohjala, et al.	All	
	60.	WO 92/12985 A1	08-06-1992	Thorn, et al.	All	
	61.	WO 92/19629 A1	11-12-1992	Mori, et al.	All	
	62.	WO 93/14081	07-22-1993	Adams, et al.	All	
	63.	WO 93/15610 A1	08-19-1993	Cox, et al.	All	
	64.	WO 94 07867	04-14-1994	Mylari, et al.	All	
	65.	WO 95/07920	03-23-1995	Bischofberger, et al.	All	
	66.	WO 95/14385 A1	06-01-1995	Lindell, et al.	All	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/780,948
				Filing Date	February 17, 2004
				First Named Inventor	Mark D. Erion
				Art Unit	1623
				Examiner Name	Patrick T. Lewis, Ph.D.
Sheet	3	of	9	Attorney Docket Number	MET-016XDT

	67.	WO 98/04528	02-05-1998	Schmidt, et al.	All	
--	-----	-------------	------------	-----------------	-----	--

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
	68.	Alimov, et al. "Preparation of amides on N-Phosphorylated amino carboxylic acids", Online, Chemical abstracts, Columbus, OH, April 25, 2003	
	69.	Arcoria, et al. "Reactions of Triethyl Phosphite with 2-Haloacetyl-furan, -thiophene, -pyrrole and -N-methylpyrrole (1)", J. Het. Chem., 12, pp. 215-218, 1975.	
	70.	Ayral-Kaloustian, et al. "Synthesis of Partially-Protected D-fructofuranoses and D-fructose-6-phosphates" Carbohydrate Research, 214, pp.187-192, Elsevier Science Publishers B.V., 1991	
	71.	Baudy, et al. "Potent Quinoxaline-Spaced Phosphono α -Amino Acids of the AP-6 Type as Competitive NMDA Antagonists: Synthesis and Biological Evaluation", J. Med. Chem. Vol. 36, No. 3, pp.331-342, 1992.	
	72.	Banker (Modern Pharmaceuticals) Banker, G.S. et al. "Modern Pharmaceuticals, 3ed", Marcel Dekker, New York, 1996, pp. 451.	
	73.	Benzaria, et al. "Synthesis in Vitro Antiviral Evaluation and Stability Studies of Bis(S-acyl-2-thioethyl) Ester Derivatives of 9-(2-(Phosphonomethoxy) ethyl]adenine (PMEA) as Potebtuak PMEA Prodrugs with Improved Oral Bioavailability", J. Med. Chem., Vol. 39, pp. 4958-4965, 1996.	
	74.	Burke, et al. "Stereoselective Syntheses of the Rhizoxin C(1)-C(9) and C(12)--C(26) Subunits", Tetrahedron Letters, Vol. 39, pp. 2239-2242, 1998.	
	75.	Corsano, et al. "A New Synthesis of Unsaturated Phosphonates (*) (**)", Gazzetta Chimica Italiana, Vol. 119, pp. 597-599, 1989.	
	76.	De Lambaert, et al. "N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endopeptidase (NEP, EC 3.4.24.11) Inhibitors", J. Med. Chem, pp. 498-511, 1994.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/780,948
				Filing Date	February 17, 2004
				First Named Inventor	Mark D. Erion
				Art Unit	1623
				Examiner Name	Patrick T. Lewis, Ph.D.
Sheet	4	of	9	Attorney Docket Number	MET-016XDT

	77.	Dizieree, et al. "A New Simple Method for the Synthesis of 1-Alkynylphosphonates using (EtO) ₂ P(O)CCl ₃ as Precursor", Tetrahedron Letters Vol. 37, No. 11, pp. 1783-1786, 1996.	
	78.	Ebetino, et al. "A Stereoselective Process for the Preparation of Novel Phosphonoalkylphosphinates", Journal of Organometallic Chemistry Vol. 529, pp. 135-142, 1997.	
	79.	Farquhar, et al. "Biologically Reversible Phosphate-Protective Groups", Journal of Pharmaceutical Sciences Vol. 72, pp. 324-325, 1983.	
	80.	Foley, et al. "Rationale and Application of Fatty Acid Oxidation Inhibitors in Treatment of Diabetes Mellitus", Diabetes Care, Vol. 15, No. 6, pp. 773-784, 1992.	
	81.	Franchetti, et al. "Acyclic Nucleotides Related to Clitocine: Synthesis and Anti-HIV Activity", Nucleosides & Nucleotides Vol. 14, No. 3-5, pp. 607-610, 1995.	
	82.	Freeman, et al. "Prodrug Design for Phosphates and Phosphonates", Progress in Medicinal Chemistry, Vol. 34, pp. 112-147, 1997.	
	83.	Fujita, et al. "Organic Synthesis Utilizing Thiazolidine and The Related Heterocycles", Heterocycles Vol. 21, No. 1, pp. 41-60, 1984.	
	84.	Garuti, et al. "Synthesis and Biological Evaluation of Some New Phosphates", Pharmazie Vol. 47, pp. 295-297, 1992.	
	85.	Gastaldelli, et al. "Influence of Obesity and Type 2 Diabetes on Gluconeogenesis and Glucose Output in Humans", Diabetes, Vol. 49, pp. 1367-1373, 2000.	
	86.	Gerich, et al. "Matching Treatment to Pathophysiology in Type 2 Diabetes", Clinical Therapeutics, Vol. 23, No. 5, pp. 646-659, 2001.	
	87.	Gohda, et al. "Theoretical Evidence of the Existence of a Diazafulvene Intermediate in the reaction Pathway of Imidazoleglycerol Phosphate Dehydratase: Design of Novel and Potent Heterocycle Structure for the Inhibitor on the Basis of the Electronic Structure-Activity Relationship Study", Biochemica et Biophysica Acta, Vol. 1385, pp. 107-114, 1998.	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/780,948
				Filing Date	February 17, 2004
				First Named Inventor	Mark D. Erion
				Art Unit	1623
				Examiner Name	Patrick T. Lewis, Ph.D.
Sheet	5	of	9	Attorney Docket Number	MET-016XDT

88.	Groop, "Sulfonylureas In Niddm", Diabetes Care, Vol. 15, No. 6, pp. 737-754, 1992.	
89.	Harada, et al. "Resolution of 1,3-Alkanediois via Chiral Spiroketal Derived from £Menthone" Tetrahedron Letters Vol. 28, No. 41, pp. 4843-4846, 1987.	
90.	Holst, et al. "Inhibition of the Activity of Dipeptidyl-Peptidase IV as a Treatment for Type 2 Diabetes", Diabetes Vol. 47, pp. 1663-1670, 1998.	
91.	Hoover, et al. "Indole-2-Carboxamide Inhibitor of Human Liver Glycogen Phosphorylase", J. Med. Chem. Vol. 41, pp. 2934-2938, 1998.	
92.	Hundal, et al. "Mechanism by Which Metformin Reduces Glucose Production in Type 2 Diabetes", Diabetes, Vol. 49, pp. 2063-2069, 2000.	
93.	Khamnei, et al. "Neighboring Group Catalysis in the Design of Nucleotide Prodrugs." J. Med. Chem. Vol. 39, pp. 4109-4115, 1996.	
94.	Kolyamshin, et al. "Phosphorus-Containing Small Rings. VII* Amino Phosphorus Esters with a 2, 2-Dichlorocyclo-propyl Fragment", Russian Journal of Gen. Chem., Vol. 63, No. 1, pp. 29-33, 1993.	
95.	Magnusson, et al. "Increased Rate of Gluconeogenesis in Type II Diabetes Mellitus." J. Clin. Invest., Vol. 90, pp. 1323-1327, 1992.	
96.	Maier, et al. "Organic Phosphorus Compounds 97.1 Synthesis and Properties of 1-Amino-2-Aryl-and-2-Pyridyl-Ethylphosphonic Acids and Derivates", Phosphorus, Sulfur and Silicone, Vol. 62, pp. 15-27, 1991.	
97.	Maruszewska-Wieczorwska, et al. "Synthesis of 2-(Pyridyl)ethylphosphonic Acids and Esters", Chemical Abstracts, Vol. 23, pp. 1886-1889, 1958.	
98.	Maruszewska-Wieczorwska, et al. "Alkyl and Alkenyl Pyridines, Part VII. 3-(2-Pyridyl)-Propylphosphonic Acid Alkyl I Alkenylpyridine, VII. Kwas 3-(2-Pyridyl)-Propylfosfonowy", Roczniki Chemii Ann Soc. Chim. Polonorum Vol. 37, pp. 1315, 1963.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/780,948
				Filing Date	February 17, 2004
				First Named Inventor	Mark D. Erion
				Art Unit	1623
				Examiner Name	Patrick T. Lewis, Ph.D.
Sheet	6	of	9	Attorney Docket Number	MET-016XDT

	99.	Menard, et al. "Synthesis and Preliminary Evaluatin of Chelating Resins Containing a-aminoalkylphosphonic Groups", Reactive Polymers Vol. 32, pp. 201-212, 1994.	
	100.	Mikhailyuchenko, et al. "2-Chloro-1-(Diethoxyphosphinyl)Ethyl Isocyanate", Institue of Organic Chemistry, Vol. 47, No. 10, pp. 2011-2012, October 1977.	
	101.	Mikityuk, et al. "C-Acylation of Diazomethane with (Diethoxy-phosphinyl)Acetyl Chloride", UDC, Vol. 54, No. 7, pp. 1669-1770, July 1987.	
	102.	Mitchell, et al. "Bioreversible Protective for the Phospho Group: Bioactivation of the Di(4-acyloxybenzyl) and Mono(4-acyloxybenzyl) Phosphoesters of Methylphosphonate and Phosphonoacetate", J.Chem. Soc. Perkin Trans. Ipp., pp. 2345-2353, 1992.	
	103.	Mori, et al. "Synthesis of Inhibitors of Imidazole Glycerol Phosphate Dehydratase", J. Am chem Soc. Vol. 117, pp. 4411-4412, 1995	
	104.	Morita, et al. "Synthesis and Antihypertensive Activities of 1, 4-Dihydropyridine-5-phosphonate Derivatives." Chem. Pharm Bull, Vol. 35, No. 9, pp. 3898-3904, 1987.	
	105.	Nauck, et al. "Influence of Glucagon-Like Peptide 1 on Fasting Glycemia in Type 2 Diabetic Patients Treated with Insulin After Sulfonylurea Secondary Failure" Diabetes Care, Vol. 2, No. 11, pp. 1925-1931, 1998.	
	106.	Newsholme, et al. "Interaction of Some Biochemical and Physiologic Effects of insulin That May Play a Role in the Control of Blood Glucose Concentration", Diabetes Mellitus Chapter Vol. 28, pp. 263-275, 1996.	
	107.	O'Donnell, et al. "Preparation of an a-Aminophosphonate Cation Equivalent and its Reaction with organoboranes", Tetrahedron Letters, Vol. 35, No. 3, pp. 6421-6424, 1994.	
	108.	Palacios, et al. "A "One Pot"Synthesis of Polysubstituted Pyridines from Metallated Alkylphosphonates, Nitriles and a, β -Unsaturated Ketones", Tetrahedron Letters Vol. 37, No. 26, pp. 4577-4580, 1996.	
	109.	Palacios, et al. "A New and Efficient Strategy for the Preparation of 1, 5, 2-Diazaphosphorines from Primary β -Enaminophosphonates", Tetrahedron Lett., pp. 3091-3104, 1999.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/780,948
				Filing Date	February 17, 2004
				First Named Inventor	Mark D. Erion
				Art Unit	1623
				Examiner Name	Patrick T. Lewis, Ph.D.
Sheet	7	of	9	Attorney Docket Number	MET-016XDT

	110.	Palacios, et al. "A Simple and Efficient Strategy for the Preparation of 5-Phosphorylated Imidazol-2-ones from Primary β -Enamiophosphonates", Tetrahedron Vol. 54, pp. 2281-2288, 1998.	
	111.	Panten, et al. "Control of Insulin Secretion by Sulfonylureas, Meglitinide and Diazoxide in Relation to Their Binding to the Sulfonylurea Receptor in Pancreatic Islets", Biochemical Pharmacology, Vol. 38, No. 8, pp. 1217-1229, 1989.	
	112.	Perriello, et al. "Evidence of Increased Systemic Glucose Production and Gluconeogenesis in an Early Stage of NIDDM", Diabetes, Vol. 46, pp. 1010-1016, 1997.	
	113.	Petersen, et al. "Effects of a Novel Glucagon Receptor Antagonist (Bay 27-9955) on Glucagon-Stimulated Glucose Production in Humans", Diabetologia, Vol. 44, pp. 2018-2024, 2001.	
	114.	Puech, et al. "Intracellular delivery of Nucleoside monophosphates through a reductase-mediated activation process", Antiviral Research Vol. 22, pp. 155-174, 1993.	
	115.	Reaven, et al. "Effects of Acarbose on Carbohydrate and Liquid Metabolism in NIDDM Patients Poorly Controlled by Sulfonylureas", Diabetes Care, Vol. 13, Suppl. 3, pp. 32-36, 1990.	
	116.	Reznick, et al. "Synthesis and Properties of Pyrimidinylalkylphosphonic Acids." 8. Interaction of Some Hydroxypyrimidines With Formaldehyde and Some Phosphorus (III) Derivatives, Organometallics, Vol. 83, pp. 523, 1975.	
	117.	Reznick, et al. "Synthesis and Properties of Pyrimidinylalkylphosphonic Acids., 6. Reaction of some Hydroxypyrimidines with Dibutyl 3-Chlorophosphonate", Chem Abs, Vol. 79, pp. 380, 1973.	
	118.	Rizzi, et al. "PPN-type Nitrones: Preparation and use of a new series of β -phosphorylated spin-trapping agents", J. Chem. Soc. Perkins Trans., Vol. 2, pp. 2513-2518, 1997.	
	119.	Serafinowska, et al. "Synthesis and in Vivo Evaluation of Prodrugs of 9-[2-(Phosphonomethoxy)ethoxy]adenine", J. Med. Chem., Vol. 38, pp. 1372-1379, 1995.	
	120.	Siddiqui, et al. "The Presence of Substituents on the Aryl Moiety of the Aryl Phosphoramidate Derivative of d4T Enhances Anti-HIV Efficacy in Cell Culture: A Structure--Activity Relationship", J. Med. Chem. Vol. 42, pp. 393-399, 1999.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/780,948
				Filing Date	February 17, 2004
				First Named Inventor	Mark D. Erion
				Art Unit	1623
				Examiner Name	Patrick T. Lewis, Ph.D.
Sheet	8	of	9	Attorney Docket Number	MET-016XDT

	121.	Simonson, et al. "Efficacy, Safety, and Dose-Response Characteristics of Glipizide Gastrontestinal Therapeutic System on Glycemic Control and Insulin Secretion in NIDDM", Diabetes Care, Vol. 20, No. 4, pp. 597-606, 1997.	
	122.	Smith, et al. "Synthesis and Biological Activity of Novel Cephalosporins Containing a (Z)-Vinyl Dimethylphosphonate Group", Vol. 48, No. 1, pp. 73-82, 1995.	
	123.	Starrett, et al. "Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adebube (PNEA)m" J. Med. Chem. Vol. 37, No. 12, 1857-1864, 1994.	
	124.	Szczepaniak, et al. "Phosphoroorganic Complexones, Part VIII*. N-(Picolylamino)Isopropylphosphonic Acids", Polish J. of Chem. Vol. 52, pp. 721-726, 1978.	
	125.	Thompson, et al. "Pramlintide, a Synthetic Analog of Human Amylin, Improves the Metabolic Profile of Patients with Type 2 Diabetes Using Insulin", Diabetes Care, Vol. 21, No. 6, pp. 987-993, 1998.	
	126.	Turner, et al. "Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus", JAMA, Vol. 281, No. 21, pp. 2005-2012, 1999.	
	127.	Unger, et al. "How Obesity Causes Diabetes in Zucker Diabetic Fatty Rats", Trends Endocrinol Metab. Vol. 7, pp. 276-282, Elsevier Science Inc., 1997.	
	128.	Wajngot, et al. "Quantitative Contributions of Gluconeogenesis to Glucose Production During Fasting in Type 2 Diabetes Mellitus", Metabolism, Vol. 50, No. 1, pp. 47-52, 2001.	
	129.	Waschbusch, et al. "A New Route to a-Fluorovinylphosphonates Utilizing Peterson Olefination Methodology", tetrahedron Vol. 52, No. 45, pp. 14199-14216, 1996.	
	130.	Waschbusch, et al. "A Useful magnesium reagent for the preparation of 1, 1-difluoro-2-hydroxyphosphonates from diethyl bromodifluoromethylphosphonate via a metal-halogen exchange reaction", Journal of Organometallic Chemistry Vol. 529, pp. 267-278, 1997.	
	131.	Wolff, Manfred E. "Burger's Medicinal Chemistry and Drug Discovery", 5 th Edition, Vol. 1, John Wiley & Sons, 1995, pp. 975-977.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/780,948
				Filing Date	February 17, 2004
				First Named Inventor	Mark D. Erion
				Art Unit	1623
				Examiner Name	Patrick T. Lewis, Ph.D.
Sheet	9	of	9	Attorney Docket Number	MET-016XDT

	132.	Yokoo, et al. "Synthesis, Antibacterial Activity and Oral Absorption of New 3-[(Z)-2-Methoxycarbonylvinylthio]-7 β -(Z)-2-(2-Aminothiazol-4-yl)-2-(Oxyimino)Acetamido]Cephalosporins", J. of Antibiotics, Vol. 45, No. 6, pp. 932-939, 1992.	
	133.	Yoshino, et al. "Organic Phosphorus Compounds. 2. Synthesis and Coronary Vasodilator Activity of (Benzothiazolylbenzyl)phosphonate Derivatives," J./ Med. Cem. Vol. 32, pp. 1528-1532, 1989.	
	134.	Zhao, et al. "Synthesis of Trans-4-Alkenyl Oxazoles", Tetrahedron Letters, Vol. 32, No. 13, pp. 1609-1612, 1991.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.